Neoplasms

All Conditions

Digestive System Diseases

Nutritional and Metabolic Diseases

Adenocarcinoma

Celiac Disease

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Central Nervous System Depressants

All Drugs and Chemicals

Analgesics

Gastrointestinal Agents

Ropivacaine

Analgesics, Opioid

Pancrelipase

Pancreatin

Anesthetics

Anesthetics, Local

Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug.

The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.

Intervention: Drug: 20 mL of 0.5% Ropivacaine

Patients in the control arm will undergo the celiac plexus block procedure as well. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.

Intervention: Drug: 20 mL of 0.9% normal saline

Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.

Ropivacaine 0.5%

Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.

Normal Saline

Ruan

The goal of this study is to assess the efficacy of intraoperative celiac plexus block (CPB) to reduce opioid consumption following laparoscopic hepato-pancreato-biliary surgery

A bilateral CPB is convenient and safe to perform under the direct laparoscopic vision of the surgeons during surgery; however, perspective data are warranted. The investigators hypothesize that a bilateral CPB using 0.5% ropivacaine will improve the quality of recovery following a laparoscopic hepato-pancreato-biliary surgery. The primary endpoint is the Postoperative opioid use. Secondary endpoints include acute postoperative pain, opioid consumption, the incidence of postoperative nausea or vomiting (PONV), the 15-item quality of recovery questionnaire (QoR-15), length of post-anesthesia care unit (PACU) stay, length of post-operative hospital stay, and chronic post-surgical pain at 90 d after surgery.

Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery

Celiac Plexus Block to Reduce Opioid Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery: a Randomized Controlled Trial

The primary outcome will be morphine equivalent during the first postoperative 24 h

Patients will be recorded for up to 72 h postoperative opioid consumption.

Patients will be asked to complete a daily diary up to 72 h that records numeric pain rating scale

Incidence of postoeprative vomiting will be recorded for up to 72 h

Patients will be asked to complete a 15-item quality of recovery questionnaire up to 72 h after surgery

Sixth Affiliated Hospital, Sun Yat-sen University

Rare Diseases

Primary Liver Cancer

Antineoplastic Agents

Micronutrients

Hematinics

Anti-Infective Agents

Vitamins

Doxorubicin

Liposomal doxorubicin

Leucovorin

Fluorouracil

Raltitrexed

Cisplatin

Oxaliplatin

Liver Extracts

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

Antidotes

Protective Agents

Folic Acid

Vitamin B Complex

Trace Elements

Folic Acid Antagonists

Folate

Vitamin B9

Folinic Acid

The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on 3D-HDRA results. Precise transarterial chemoembolization at 1-month intervals for 4 months after surgery.

The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization. Empirical transarterial chemoembolization at 1-month intervals for 4 months after surgery.

130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Lobaplatin

50 mg per square body surface area was used for monthly transhepatic arterial infusions.

Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.

Oxaliplatin, Leucovorin, fluorouracil

Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.

Lobaplatin, Raltitrexed

Mingxin Pan, Prof

This Randomized Controlled Trial was to clarity the clinical feasibility of 3D-HDRA results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.

Data of Patients who received 3D-HDRA after primary liver cancer radical reaction and received Transarterial Chemoembolization #will be collected #excluding incomplete data.

The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was the adverse event.

The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on 3D-HDRA results, and the control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization.

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Applicability of 3D Histoculture Drug Response Assay(3D-HDRA) in Patients With Primary Liver Cancer: A Randomized Controlled Trial

The one-year DFS rate is defined as the percentage of participants who have not accrued disease at the time of 1 year

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery	NCT06214533	Pancreatic Duct... Liver, Cancer o...	Ropivacaine 0.5... Normal Saline	18 Years -	Sixth Affiliated Hospital, Sun Yat-sen University
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial	NCT05701436	Liver, Cancer o...	Oxaliplatin Doxorubicin Lobaplatin Cisplatin Oxaliplatin, Le... Lobaplatin, Ral...	18 Years - 75 Years	Zhujiang Hospital
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial	NCT05701436	Liver, Cancer o...	Oxaliplatin Doxorubicin Lobaplatin Cisplatin Oxaliplatin, Le... Lobaplatin, Ral...	18 Years - 75 Years	Zhujiang Hospital

Spots Global Cancer Trial Database for liver, cancer of, primary resectable